Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I646147-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $200.90 | |
I646147-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $300.90 |
Synonyms | A4YJ7J11TG | IOXILAN [JAN] | Ioxilane | UNII-A4YJ7J11TG | V08AB12 | IOXILAN [INN] | NSC 760056 | SR-01000883963-1 | Ioxilan(400 mg) | Imagenil | IOXILAN [USP-RS] | 1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N1-(2,3-DIHYDROXYPROPYL)-N3- |
---|---|
Specifications & Purity | ≥98% |
Biochemical and Physiological Mechanisms | Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Mechanism of action | Diagnostic agent |
Product Description | Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs . In Vitro As a low-osmolar nonionic monomer, Ioxilan increases the safety and tolerance of X-ray contrast agents. The development of Ioxilan is based on the introduction of a double methylene as a hydrophobic region and masking it with a hydrophilic hydroxyl group could lower the osmolality without adversely affecting the biological tolerance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
ALogP | -2.4 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
---|---|
INCHI | InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) |
InChi Key | UUMLTINZBQPNGF-UHFFFAOYSA-N |
Canonical SMILES | CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I |
Isomeric SMILES | CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I |
PubChem CID | 3743 |
Molecular Weight | 791.11 |
Enter Lot Number to search for COA:
Solubility | DMSO : ≥ 250 mg/mL (316.01 mM) |
---|